Opinion|Videos|June 24, 2024
COLLISION: Surgery vs Thermal Ablation for Small-Size Colorectal Liver Mets
The Oncology Brothers and Mark A. Lewis, MD, review recent updates from the COLLISION study that were presented at the 2024 ASCO Annual Meeting.
Advertisement
Episodes in this series
Advertisement
Related to this article
Proton therapy did not improve overall survival vs photon therapy in advanced hepatocellular carcinoma in the phase 3 NRG-GI003 trial.
The oral FGFR2 inhibitor lirafugratinib is now FDA approved for the second-line treatment of cholangiocarcinoma harboring FGFR2 alterations.
New 177Lu-dotatate radioligand therapy expands options for SSTR+ GEP-NETs, backed by NETTER-1 efficacy and key safety guidance.
The FDA has recommended conducting a new trial showing an OS benefit with tovecimig in biliary cancer before submitting a BLA.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
2
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
3
Denosumab Biosimilar Approved For Existing Oncology Indications
4
CEPHEUS and Frontline Treatment in Newly Diagnosed Multiple Myeloma
5